These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
139 related articles for article (PubMed ID: 34994965)
101. Development, validation and implementation of the medical affairs pharmaceutical physician work-related quality of life instrument. Jandhyala R Curr Med Res Opin; 2023 Dec; 39(12):1567-1574. PubMed ID: 36719367 [TBL] [Abstract][Full Text] [Related]
102. Design, validation and implementation of the post-acute (long) COVID-19 quality of life (PAC-19QoL) instrument. Jandhyala R Health Qual Life Outcomes; 2021 Sep; 19(1):229. PubMed ID: 34583690 [TBL] [Abstract][Full Text] [Related]
103. A medicine adoption model for assessing the expected effects of additional real-world evidence (RWE) at product launch. Jandhyala R Curr Med Res Opin; 2021 Sep; 37(9):1645-1655. PubMed ID: 34176383 [TBL] [Abstract][Full Text] [Related]
105. The multiple stakeholder approach to real-world evidence (RWE) generation: observing multidisciplinary expert consensus on quality indicators of rare disease patient registries (RDRs). Jandhyala R Curr Med Res Opin; 2021 Jul; 37(7):1249-1257. PubMed ID: 33989087 [TBL] [Abstract][Full Text] [Related]
106. Neutral theory: applicability and neutrality of using generic health-related quality of life tools in diseases or conditions where specific tools are available. Jandhyala R BMC Med Res Methodol; 2021 Apr; 21(1):86. PubMed ID: 33902436 [TBL] [Abstract][Full Text] [Related]
107. Delphi, non-RAND modified Delphi, RAND/UCLA appropriateness method and a novel group awareness and consensus methodology for consensus measurement: a systematic literature review. Jandhyala R Curr Med Res Opin; 2020 Nov; 36(11):1873-1887. PubMed ID: 32866051 [TBL] [Abstract][Full Text] [Related]
108. A novel method for observing proportional group awareness and consensus of items arising from list-generating questioning. Jandhyala R Curr Med Res Opin; 2020 May; 36(5):883-893. PubMed ID: 32098506 [No Abstract] [Full Text] [Related]
109. On-Label or Off-Label? Overcoming Regulatory and Financial Barriers to Bring Repurposed Medicines to Cancer Patients. Verbaanderd C; Rooman I; Meheus L; Huys I Front Pharmacol; 2019; 10():1664. PubMed ID: 32076405 [TBL] [Abstract][Full Text] [Related]
110. Influence of Pharmaceutical Company Engagement Activities on the Decision to Prescribe: A Pilot Survey of UK Rare Disease Medicine Prescribers. Jandhyala R Pharmaceut Med; 2020 Apr; 34(2):127-134. PubMed ID: 32048216 [TBL] [Abstract][Full Text] [Related]
111. What matters most? Different stakeholder perspectives on estimands for an invented case study in COPD. Keene ON; Ruberg S; Schacht A; Akacha M; Lawrance R; Berglind A; Wright D Pharm Stat; 2020 Jul; 19(4):370-387. PubMed ID: 31919979 [TBL] [Abstract][Full Text] [Related]
112. Physicians in the pharmaceutical industry: their roles, motivations, and perspectives. Sweiti H; Wiegand F; Bug C; Vogel M; Lavie F; Winiger-Candolfi I; Schuier M Drug Discov Today; 2019 Sep; 24(9):1865-1870. PubMed ID: 31158509 [TBL] [Abstract][Full Text] [Related]
113. Evolving role of pharmaceutical physicians in medical evidence and education. Setia S; Ryan NJ; Nair PS; Ching E; Subramaniam K Adv Med Educ Pract; 2018; 9():777-790. PubMed ID: 30464675 [TBL] [Abstract][Full Text] [Related]
114. Real world evidence (RWE) - a disruptive innovation or the quiet evolution of medical evidence generation? Khosla S; White R; Medina J; Ouwens M; Emmas C; Koder T; Male G; Leonard S F1000Res; 2018; 7():111. PubMed ID: 30026923 [TBL] [Abstract][Full Text] [Related]
115. Interactions between physicians and the pharmaceutical industry generally and sales representatives specifically and their association with physicians' attitudes and prescribing habits: a systematic review. Fickweiler F; Fickweiler W; Urbach E BMJ Open; 2017 Sep; 7(9):e016408. PubMed ID: 28963287 [TBL] [Abstract][Full Text] [Related]
116. Hypertension and blood pressure variability management practices among physicians in Singapore. Setia S; Subramaniam K; Tay JC; Teo BW Vasc Health Risk Manag; 2017; 13():275-285. PubMed ID: 28761353 [TBL] [Abstract][Full Text] [Related]
117. Ambulatory and home blood pressure monitoring: gaps between clinical guidelines and clinical practice in Singapore. Setia S; Subramaniam K; Teo BW; Tay JC Int J Gen Med; 2017; 10():189-197. PubMed ID: 28721085 [TBL] [Abstract][Full Text] [Related]
118. Doctors' knowledge, attitudes, and compliance with 2013 ACC/AHA guidelines for prevention of atherosclerotic cardiovascular disease in Singapore. Setia S; Fung SS; Waters DD Vasc Health Risk Manag; 2015; 11():303-10. PubMed ID: 26082642 [TBL] [Abstract][Full Text] [Related]
119. Interprofessional collaboration in research, education, and clinical practice: working together for a better future. Green BN; Johnson CD J Chiropr Educ; 2015 Mar; 29(1):1-10. PubMed ID: 25594446 [TBL] [Abstract][Full Text] [Related]
120. Core competencies for pharmaceutical physicians and drug development scientists. Silva H; Stonier P; Buhler F; Deslypere JP; Criscuolo D; Nell G; Massud J; Geary S; Schenk J; Kerpel-Fronius S; Koski G; Clemens N; Klingmann I; Kesselring G; van Olden R; Dubois D Front Pharmacol; 2013; 4():105. PubMed ID: 23986704 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]